Ravinder N. Maini | Academic Influence

Ravinder N. Maini's AcademicInfluence.com Rankings

Ravinder N. Maini

Philosophy

#5371

World Rank

#8144

Historical Rank

Logic

#2659

World Rank

#3680

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Why Is Ravinder N. Maini Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Sir Ravinder Nath Maini is an Indian-born British rheumatologist and academic who is an emeritus professor at Imperial College London. He led the Kennedy Institute of Rheumatology. Biography Maini was born in Ludhiana, Punjab, British India, to Sir Amar Maini, a Kenyan-born lawyer and Ugandan politician, and his wife, Sam Saheli Mehra. His younger brother is academic Yoginder Nath Tidu Maini. Ravinder completed his bachelor's degree at Sidney Sussex College, Cambridge. In the 1980s, Maini, Marc Feldmann and Fionula Brennan identified TNF alpha as a key cytokine in the process of rheumatoid arthritis.

(See a Problem?)

Ravinder N. Maini's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. (2000) (3063)
Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial (1999) (2434)
Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. (1998) (1712)
Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. (2004) (1167)
INHIBITORY EFFECT OF TNFα ANTIBODIES ON SYNOVIAL CELL INTERLEUKIN-1 PRODUCTION IN RHEUMATOID ARTHRITIS (1989) (1152)
Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis. (1992) (1033)
Range of antinuclear antibodies in "healthy" individuals. (1997) (779)
Mesenchymal precursor cells in the blood of normal individuals (2000) (763)
Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. (2006) (666)
Localization of tumor necrosis factor alpha in synovial tissues and at the cartilage-pannus junction in patients with rheumatoid arthritis. (1991) (619)
Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-alpha therapy in rheumatoid arthritis. (1999) (598)
Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebo-controlled trials. (2000) (546)
Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate. (2004) (540)
The Role of Cytokines in Rheumatoid Arthritis (1996) (533)
Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: a detailed subanalysis of data from the anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study. (2005) (477)
Trials of anti-tumour necrosis factor therapy for COVID-19 are urgently needed (2020) (450)
Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab: results from the ASPIRE trial. (2006) (444)
Reduction of chemokine levels and leukocyte traffic to joints by tumor necrosis factor alpha blockade in patients with rheumatoid arthritis. (2000) (428)
Decrease in cellularity and expression of adhesion molecules by anti-tumor necrosis factor alpha monoclonal antibody treatment in patients with rheumatoid arthritis. (1996) (410)
Modulation of angiogenic vascular endothelial growth factor by tumor necrosis factor alpha and interleukin-1 in rheumatoid arthritis. (1998) (370)
Increased levels of soluble tumor necrosis factor receptors in the sera and synovial fluid of patients with rheumatic diseases. (1992) (353)
Interleukin-1 and tumour necrosis factor mRNA expression in rheumatoid arthritis: prolonged production of IL-1 alpha. (1988) (344)
TNF defined as a therapeutic target for rheumatoid arthritis and other autoimmune diseases (2003) (330)
Comparison of ultrasonographic assessment of synovitis and joint vascularity with radiographic evaluation in a randomized, placebo-controlled study of infliximab therapy in early rheumatoid arthritis. (2004) (323)
Expression of granulocyte‐macrophage colony‐stimulating factor in rheumatoid arthritis: Regulation by tumor necrosis factor‐α (1991) (304)
Detection of interleukin 8 biological activity in synovial fluids from patients with rheumatoid arthritis and production of interleukin 8 mRNA by isolated synovial cells (1990) (284)
Deactivation of vascular endothelium by monoclonal anti-tumor necrosis factor alpha antibody in rheumatoid arthritis. (1996) (261)
Raised serum vascular endothelial growth factor levels are associated with destructive change in inflammatory arthritis. (2001) (259)
Lasker Clinical Medical Research Award. TNF defined as a therapeutic target for rheumatoid arthritis and other autoimmune diseases. (2003) (256)
Radiographic changes in rheumatoid arthritis patients attaining different disease activity states with methotrexate monotherapy and infliximab plus methotrexate: the impacts of remission and tumour necrosis factor blockade (2008) (256)
Rheumatoid Arthritis (1996) (252)
Infliximab in active early rheumatoid arthritis (2004) (245)
Detection of cytokines at the cartilage/pannus junction in patients with rheumatoid arthritis: implications for the role of cytokines in cartilage destruction and repair. (1992) (244)
Localization of tumor necrosis factor receptors in the synovial tissue and cartilage-pannus junction in patients with rheumatoid arthritis. Implications for local actions of tumor necrosis factor alpha. (1992) (227)
A rheumatoid arthritis B cell subset expresses a phenotype similar to that in chronic lymphocytic leukemia. (1985) (226)
Anti-cytokine therapy for rheumatoid arthritis. (2000) (225)
Manual of Biological Markers of Disease (1996) (199)
Monoclonal anti‐TNFα Antibody as a Probe of Pathogenesis and Therapy of Rheumatoid Disease (1995) (191)
Factors predicting a poor life prognosis in rheumatoid arthritis: an eight year prospective study. (1989) (188)
Cytokines and anti-cytokine biologicals in autoimmunity: present and future. (2002) (177)
Correlation between serum levels of soluble tumor necrosis factor receptor and disease activity in systemic lupus erythematosus. (1993) (176)
A critical evaluation of enzyme immunoassays for detection of antinuclear autoantibodies of defined specificities. I. Precision, sensitivity, and specificity. (1999) (176)
Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha. (2008) (156)
Detection of activated T cell products in the rheumatoid joint using cDNA probes to Interleukin-2 (IL-2) IL-2 receptor and IFN-gamma. (1988) (146)
Virus infection induces redistribution and membrane localization of the nuclear antigen La (SS-B): a possible mechanism for autoimmunity. (1989) (145)
Increased concentrations of proteoglycan components in the synovial fluids of patients with acute but not chronic joint disease. (1988) (140)
Measurement of the chemotactic complement fragment C5a in rheumatoid synovial fluids by radioimmunoassay: role of C5a in the acute inflammatory phase. (1990) (139)
A micro-method for peripheral leucocyte migration in tuberculin sensitivity (1971) (135)
Role of pro-inflammatory cytokines in rheumatoid arthritis (2004) (134)
Interleukin-6: a new therapeutic target (2006) (131)
High level of interleukin-10 production by the activated T cell population within the rheumatoid synovial membrane. (1995) (129)
Infliximab treatment maintains employability in patients with early rheumatoid arthritis. (2006) (118)
Ro and La antigens and maternal anti-La idiotype on the surface of myocardial fibres in congenital heart block. (1991) (115)
TNF defined as a therapeutic target for rheumatoid arthritis and other autoimmune diseases (2003) (115)
HLA and rheumatoid arthritis: a combined analysis of 440 British patients. (1986) (114)
How does infliximab work in rheumatoid arthritis? (2002) (113)
Purification and characterization of the Sjögren's syndrome A and B antigens. (1983) (111)
Lymphocyte Mitogenic Factor in Man (1969) (109)
Evaluation of TNF-α and IL-1 Blockade in Collagen-Induced Arthritis and Comparison with Combined Anti-TNF-α/Anti-CD4 Therapy1 (2000) (107)
Anti‐IL‐12 and anti‐TNF antibodies synergistically suppress the progression of murine collagen‐induced arthritis (1999) (104)
Anti-TNF Therapy, from Rationale to Standard of Care: What Lessons Has It Taught Us? (2010) (103)
Autoantibody synthesis in salivary glands of Sjögren's syndrome patients. (1989) (102)
Ultrasonographic and radiographic results from a two-year controlled trial of immediate or one-year-delayed addition of infliximab to ongoing methotrexate therapy in patients with erosive early rheumatoid arthritis. (2006) (101)
Anti-TNF therapy: where have we got to in 2005? (2005) (99)
The immune response to and expression of cross-reactive retroviral gag sequences in autoimmune disease. (1992) (98)
Role of Chlamydia trachomatis and HLA-B27 in sexually acquired reactive arthritis. (1978) (98)
Antibodies to the mycobacterial 65-kd heat-shock protein are reactive with synovial tissue of adjuvant arthritic rats and patients with rheumatoid arthritis and osteoarthritis. (1990) (97)
Enhanced expression of tumor necrosis factor receptor mRNA and protein in mononuclear cells isolated from rheumatoid arthritis synovial joints (1992) (97)
The first international standard for antibodies to double stranded DNA. (1988) (92)
Cytokine Assays: Role in Evaluation of the Pathogenesis of Autoimmunity (1991) (91)
Consequences of immunogenicity to the therapeutic monoclonal antibodies ReoPro and Remicade. (2003) (88)
Quantitation and detection of isotypes of anti-SS-B antibodies by ELISA and Farr assays using affinity purified antigens. An approach to the investigation of Sjögren's syndrome and systemic lupus erythematosus. (1983) (87)
The consensus workshops for the detection of autoantibodies to intracellular antigens in rheumatic diseases. (1991) (86)
Anaemia of chronic disease in rheumatoid arthritis: in vivo effects of tumour necrosis factor alpha blockade. (1997) (86)
Discovery of TNF-alpha as a therapeutic target in rheumatoid arthritis: preclinical and clinical studies. (2002) (85)
TNFα Is an Effective Therapeutic Target for Rheumatoid Arthritis a (1995) (85)
TNF-alpha in rheumatoid arthritis and prospects of anti-TNF therapy. (1993) (83)
Evidence of Chlamydia trachomatis infection in sexually acquired reactive arthritis. (1980) (82)
Anti-tumour necrosis factor specific antibody (infliximab) treatment provides insights into the pathophysiology of rheumatoid arthritis (1999) (81)
The transfer of a laboratory based hypothesis to a clinically useful therapy: the development of anti-TNF therapy of rheumatoid arthritis. (2004) (77)
Possible induction of systemic lupus erythematosus by human parvovirus. (1992) (76)
Association between baseline radiographic damage and improvement in physical function after treatment of patients with rheumatoid arthritis (2004) (75)
Expression of intercellular adhesion molecule-1 and lymphocyte function-associated antigen-3 on human thyroid epithelial cells in Graves' and Hashimoto's diseases. (1990) (74)
Autoantibodies in malaria, tuberculosis and hepatitis B in a West African population (1993) (70)
HLA antigen associations with extra-articular rheumatoid arthritis. (1984) (67)
Cartilage destruction and bone erosion in arthritis: the role of tumour necrosis factor α (2000) (67)
Standardization of the leucocyte migration test. (1973) (66)
Human anti-DNA antibody: reference standards for diagnosis and management of systemic lupus erythematosus. (1975) (65)
Suppression of fever and the acute-phase response in a patient with juvenile chronic arthritis treated with monoclonal antibody to tumour necrosis factor-alpha (cA2). (1997) (65)
Consensus statement on the initiation and continuation of tumour necrosis factor blocking therapies in rheumatoid arthritis* (2000) (64)
Arthritis in scleroderma. (1995) (63)
Lupus Erythematosus 2nd ed (1975) (61)
Monoclonal antibodies to the Sjögren's syndrome associated antigen SS-B (La). (1985) (61)
Detection of cytokines at the site of tuberculin‐induced delayed‐type hypersensitivity in man (1992) (61)
Clinical, serological, and HLA phenotype subsets in Sjögren's syndrome. (1989) (60)
A critical evaluation of enzyme immunoassay kits for detection of antinuclear autoantibodies of defined specificities. III. Comparative performance characteristics of academic and manufacturers' laboratories. (2003) (59)
The role of the B cells in the adoptive transfer of collagen‐induced arthritis from DBA/1 (H‐2q) to SCID (H−2d) mice (1995) (59)
The arthropathy of Sjögren's syndrome. (1993) (59)
Definition and clinical relevance of antibodies to nuclear ribonucleoprotein and other nuclear antigens in patients with cryptogenic fibrosing alveolitis. (2015) (59)
A seroepidemiological study of cytomegalovirus and Epstein-Barr virus in rheumatoid arthritis and sicca syndrome. (1985) (56)
A critical evaluation of enzyme immunoassay kits for detection of antinuclear autoantibodies of defined specificities. II. Potential for quantitation of antibody content. (2002) (55)
The clinical features and HLA associations of reactive arthritis associated with non-gonococcal urethritis. (1979) (53)
Reference sera for antinuclear antibodies. II. Further definition of antibody specificities in international antinuclear antibody reference sera by immunofluorescence and western blotting. (1997) (53)
Anti-TNFalpha therapy of rheumatoid arthritis: what can we learn about chronic disease? (2004) (52)
Titers of antibodies to RANA in rheumatoid arthritis and normal sera. Relationship to Epstein-Barr virus infection. (1981) (52)
Increased limb involvement in murine collagen‐induced arthritis following treatment with anti‐interferon‐gamma (1993) (51)
Cross reaction of antibodies to a glycine/alanine repeat sequence of Epstein-Barr virus nuclear antigen-1 with collagen, cytokeratin, and actin. (1991) (51)
The clinical significance of mediators of cellular immunity (1971) (50)
Specificity of anti-Sm antibodies by ELISA for systemic lupus erythematosus: increased sensitivity of detection using purified peptide antigens. (1988) (50)
Interleukin-6 localisation in the synovial membrane in rheumatoid arthritis (1991) (49)
Mechanism of immune complex‐mediated damage: induction of interleukin 1 by immune complexes and synergy with interferon‐γ and tumor necrosis factor‐α (1989) (49)
Multiple sclerosis (1986) (49)
Murine lupus monoclonal antibodies define five epitopes on two different Sm polypeptides. (1986) (48)
Respiratory involvement in systemic lupus erythematosus. A clinical and immunological study. (1976) (46)
Measurement of the complement C3 breakdown product C3d by rocket immunoelectrophoresis. (1982) (45)
Detection of in vivo production of tumour necrosis factor-alpha by human thyroid epithelial cells. (1992) (44)
Sustained response to doxycycline therapy in two patients with SAPHO syndrome. (1999) (43)
Antibodies to La, Jo-1, nRNP and Sm detected by multi-track immunoblotting using a novel filter holder: a comparative study with counterimmunoelectrophoresis and immunodiffusion using sera from patients with systemic lupus erythematosus and Sjögren's syndrome. (1986) (43)
Perspectives From Masters in Rheumatology and Autoimmunity: Can We Get Closer to a Cure for Rheumatoid Arthritis? (2015) (43)
The rationale for the current boom in anti-TNFα treatment. Is there an effective means to define therapeutic targets for drugs that provide all the benefits of anti-TNFα and minimise hazards? (1999) (42)
HLA-B40: a marker for susceptibility to lung disease in rheumatoid arthritis. (1991) (42)
Human transfer factor in vitro. I. Augmentation of lymphocyte transformation to tuberculin PPD (1976) (42)
Anti-cardiolipin antibodies in infectious mononucleosis react with the membrane of activated lymphocytes. (1989) (39)
Anti-La (SS-B): a diagnostic criterion for Sjögren's syndrome? (1989) (39)
Updated consensus statement on tumour necrosis factor blocking agents for the treatment of rheumatoid arthritis (May 2000) (2000) (38)
Reference reagents for antinuclear antibodies (1988) (37)
IgE and IgE-rheumatoid factors in circulating immune complexes in rheumatoid arthritis. (1982) (36)
Differential regulation of tumour necrosis factor receptors (TNF-R) by IL-4; upregulation of P55 and P75 TNF-R on synovial joint mononuclear cells. (1993) (35)
Proceedings: Controlled trial of azathioprine in rheumatoid vasculitis. (1973) (34)
Reaction of antibodies to rheumatoid arthritis nuclear antigen with a synthetic peptide corresponding to part of Epstein-Barr nuclear antigen 1. (1988) (34)
The production of lymphocyte mitogenic factor and migration-inhibition factor by antigen-stimulated lymphocytes of subjects with grass pollen allergy. (1971) (33)
Human transfer factor in vitro. II. Augmentation of lymphocyte transformation to phytohaemagglutinin (1976) (33)
Antibodies to nuclear antigens in polymyositis: relationship to autoimmune 'overlap syndromes' and carcinoma. (1981) (33)
Interpretation of the Raji cell assay in sera containing anti-nuclear antibodies and immune complexes. (1981) (33)
Biological insights from clinical trials with anti-TNF therapy (2004) (33)
Interferon-gamma and epithelial cell activation in Sjögren's syndrome. (1995) (33)
The association of cryoglobulinaemia with nodules, vasculitis and fibrosing alveolitis in rheumatoid arthritis and their relationship to serum C1q binding activity and rheumatoid factor. (1979) (33)
Recapitulation of the round-table discussion--assessing the role of anti-tumour necrosis factor therapy in the treatment of rheumatoid arthritis. (1999) (32)
Autoimmunity in rheumatoid arthritis. An approach via a study of B lymphocytes. (1987) (32)
Morphometric comparison of synovium from patients with osteoarthritis and rheumatoid arthritis. (1988) (32)
Targeting TNF alpha for the therapy of rheumatoid arthritis. (1994) (31)
Clinical and radiological features of osteonecrosis in systemic lupus erythematosus. (1979) (31)
Placental and fetal cardiac laminin are targets for cross-reacting autoantibodies from mothers of children with congenital heart block. (1996) (31)
Antibodies to extractable nuclear antigens in rheumatoid arthritis: relationship to vasculitis and circulating immune complexes. (1980) (31)
Serological and immunogenetic markers of extraglandular primary Sjögren's syndrome. (1993) (30)
Proposal to establish a register for the long term surveillance of adverse events in patients with rheumatic diseases exposed to biological agents: the EULAR Surveillance Register for Biological Compounds (2000) (29)
Similarities in the mechanisms of action of pulse corticosteroids and anti-tumor necrosis factor ? therapy in rheumatoid arthritis (1998) (26)
Thymus and bursa dependence of lymphocyte mitogenic factor in the chicken. (1972) (25)
Synthesis of sulphated proteoglycans by rheumatoid and normal synovial tissue in culture. (1979) (24)
Access to disease modifying treatments for rheumatoid arthritis patients (1999) (23)
Soluble tumor necrosis factor receptors in arthritis. (1995) (22)
Cell-mediated immune mechanisms. (1975) (22)
Efficacy of IL-6 receptor antagonist Mra in rheumatoid arthritis patients with an incomplete response to methotrexate (CHARISMA). (2003) (22)
Antibodies to human herpesvirus-6 in Sjögren's syndrome. (1990) (21)
Increased expression of HLA-DQ antigens by interstitial cells and endothelium in the synovial membrane of rheumatoid arthritis patients compared with reactive arthritis patients. (1989) (21)
Polymorphism in the immunoglobulin VH gene V1-69 affects susceptibility to rheumatoid arthritis in subjects lacking the HLA-DRB1 shared epitope. (2002) (21)
The complement fixing ability of putative circulating immune complexes in rheumatoid arthritis and its relationship to extra-articular disease. (1982) (21)
Antibodies in rheumatoid arthritis react specifically with the glycine alanine repeat sequence of Epstein-Barr nuclear antigen-1 (2004) (21)
Pathogenesis of Rheumatoid Arthritis: Cellular and Cytokine Interactions (1992) (20)
Separation of two molecular species of the Sm antigen by affinity chromatography with murine monoclonal and human anti-nuclear autoantibodies. (1983) (20)
Future prospects for anti-cytokine treatment (2000) (18)
The response to Epstein-Barr virus infection in Sjögren's syndrome. (1989) (18)
Anti-type II collagen ELISA. Increased disease specificity following removal of anionic contaminants from salt-fractionated type II collagen. (1992) (18)
Disease modifying treatment and elective surgery in rheumatoid arthritis: the need for more data (2004) (18)
The significance of CD5+ B cells in rheumatic diseases. (1988) (18)
Histocompatibility antigens in adult obliterative bronchiolitis with or without rheumatoid arthritis. (1986) (18)
Differential induction of lupus associated antinuclear antibodies in MRL mice by monoclonal anti-Sm antibodies. (1987) (17)
Arthritis Research & Therapy evolves: online only from 2011 (2010) (17)
Preparative isolation of p67, A, B, B' and D from nRNP/Sm and Sm antigens by reverse-phase chromatography. Use in a polypeptide-specific ELISA for independent quantitation of anti-nRNP and anti-Sm antibodies. (1988) (17)
The Consensus Workshops for the Detection of Autoantibodies to Intracellular Antigens in Rheumatic Diseases: 1989-1992. (1992) (17)
Measurement of DNA antibodies by double antibody precipitation. (1973) (17)
Co-existent anti-La antibodies and rheumatoid factors bear distinct idiotypic markers. (1988) (17)
AUTOIMMUNITY TO CARDIOLIPIN IN INFECTIOUS MONONUCLEOSIS (1987) (16)
Sequence analysis of immunoglobulin heavy-chain variable region genes from the synovium of a rheumatoid arthritis patient shows little evidence of mutation but diverse CDR3. (1995) (15)
CD5+B in Rheumatoid Arthritis a (1992) (15)
In vitro immunoglobulin synthesis by lymphocytes from patients with rheumatoid arthritis. I. Effect of monocyte depletion and demonstration of an increased proportion of lymphocytes forming rosettes with mouse erythrocytes. (1983) (15)
Representative sample of rheumatoid synovium: a morphometric study. (1988) (14)
Antinuclear antibodies in the immunotaxonomy of connective tissue diseases. (1985) (14)
Anti-Clq affinity isolated circulating immune complexes correlate with extra-articular rheumatoid disease (2004) (14)
The Arthritis Research non-peer-review depository (1999) (14)
Rheumatoid and normal synovial tissue in longterm culture. Evidence of cell heterogeneity and an approach to quantitation of of populations and the effect of passage. (1978) (14)
Rheumatoid arthritis. A paradigm of inflammatory disease of the musculoskeletal system. (1998) (14)
Idiotypes on antibodies to the La (SS-B) antigen are restricted and associated with the antigen binding site. (1986) (14)
The detection by immunofluorescence of distinct cell populations producing interleukin-1α and interleukin-1β in activated human peripheral blood (1989) (14)
Phenotypic and functional features of CD5+ B lymphocytes in rheumatoid arthritis. (1988) (14)
Rheumatoid arthritis nuclear antigen and Epstein-Barr virus. (1984) (13)
Immunological intervention reveals reciprocal roles for tumor necrosis factor-α and interleukin-10 in rheumatoid arthritis and systemic lupus erythematosus (2004) (13)
Circulating immune complexes and rheumatoid arthritis: a comparison of different assay methods and their early predictive value for disease activity and outcome. (1985) (13)
Proceedings: Complement activation in Reiter's syndrome. (1975) (13)
Demonstration of an unidentified 48 kD polypeptide in circulating immune complexes in rheumatoid arthritis. (1987) (13)
The Relationship of Sjögren’s Syndrome to Rheumatoid Arthritis (1987) (12)
VEGF release is associated with hypoxia in inflammatory arthritis(.) (2000) (12)
Sexually acquired reactive arthritis. (1979) (12)
Relationship of precipitating antibodies to soluble cellular antigens and histologically defined renal lesions in systemic lupus erythematosus. (1983) (12)
Search for mycoplasma in synovial fluids from patients with rheumatoid arthritis. (1973) (12)
Individual variation of anti-Sm autoantibodies in the MRL/MP-lpr/lpr mouse: age-related increase in diversity. (1986) (12)
Analysis of a positive feedback mechanism in the anti‐Sm autoantibody response of MRL/MPJ‐lpr/lpr mice (1991) (11)
Current and new antitumor necrosis factor agents in perspective (2004) (11)
Administration of monoclonal anti-Sm antibody prolongs the survival and renal function of MRL-lpr/lpr mice. (1986) (11)
Differences in immunochemical characteristics of cryoglobulins in rheumatoid arthritis and systemic lupus erythematosus and their complement binding properties. (1984) (11)
Ruptured abdominal aorta infected with Salmonella brandenburg. (1968) (11)
Anti-idiotypic induced suppression of Sjögren's syndrome associated anti-La autoantibody secretion in vitro. (1988) (11)
Antibodies to neutrophil cytoplasmic antigens in rheumatoid arthritis. (1993) (11)
Mechanism of immune complex-mediated damage: induction of interleukin 1 by immune complexes and synergy with interferon-gamma and tumor necrosis factor-alpha. (1989) (11)
The inhibitory effect of D-penicillamine on human lymphocyte cultures stimulated by phytohaemagglutinin, the antagonistic action of L-cysteine and synergistic inhibition by copper sulphate. (1979) (10)
Rheumatoid factors and germline genes in rheumatoid arthritis: evidence of an intrinsic B-lymphocyte defect? (1994) (10)
Rheumatoid arthritis, juvenile arthritis, iridocyclitis and the Epstein-Barr virus. (1986) (10)
Reduction in cellularity and expression of adhesion molecules in rheumatoid synovial tissue after anti-TNFα monoclonal antibody treatment. (1996) (10)
Spontaneous recovery of the decreased expression in vitro of interleukin 2 receptors in rheumatoid arthritis. (1988) (10)
Heberden Oration, 1988. Exploring immune pathways in rheumatoid arthritis. (1989) (9)
Crystallization and preliminary X-ray analysis of the Fab fragment of a human monoclonal IgM rheumatoid factor (2A2). (1994) (9)
The pitfalls in the development of biologic therapy (2007) (9)
FATAL MARROW APLASIA IN PATIENT ON PENICILLAMINE (1976) (9)
SLE nephritis: an ultrastructural immunogold study to evaluate the relationship between immune complexes and the basement membrane components type IV collagen, fibronectin and heparan sulphate proteoglycans. (1990) (9)
Anti-TNF therapy from the bench to the clinic: a paradigm of translational research. (2010) (9)
Blocking tumor necrosis factor inhibits radiographic damage even in patients who show minimal or no clinical improvement: comment on the concise communication by Boers. (2002) (9)
B-lymphocyte subpopulation which forms rosettes with mouse erythrocytes increased in rheumatoid arthritis (2004) (9)
Peripheral leucocyte migration. Inhibited by diphtheroid organisms isolated from patients with rheumatoid arthritis. (1970) (9)
IS THE CLINICAL BENEFIT FROM TRANSFER FACTOR IN RHEUMATOID ARTHRITIS A PLACEBO EFFECT (1976) (8)
Purification of human autoantibodies from cross-linked antigen immunosorbents. (1987) (8)
Infliximab therapy leads to clinical and radiographic benefits in early rheumatoid arthritis patients receiving optimum methotrexate dose (2004) (8)
Role of HLA class II and cytokine expression in rheumatoid arthritis. (1988) (7)
Measurement of immunoglobulin production by peripheral blood mononuclear cells in vitro using a solid-phase immunoradiometric assay. (1981) (7)
The potential role of B-lymphocytes in the pathogenesis of rheumatoid arthritis. (1991) (7)
Immunology of the Rheumatic Diseases: Aspects of Autoimmunity (1977) (7)
The Mast Cell: Its Role in Health and Disease (1981) (7)
AUGMENTATION OF LYMPHOCYTE TRANSFORMATION BY DIALYSABLE TRANSFER FACTOR (1976) (7)
Anti-mouse red blood cell monoclonal antibodies use functionally rearranged genes from the VH J558 family and are derived from the CD5- B-lymphocyte subpopulation. (1993) (7)
Combined power color Doppler and greyscale ultrasound demonstrate an association between vascularity and erosions in rheumatoid arthritis. (2000) (7)
A micro-method forperipheral leucocyte migration intuberculin sensitivity (1971) (6)
Normal serologic response to Epstein-Barr virus in patients with Sjögren's syndrome. (1989) (6)
Enzyme-linked immunosorbant assay in the rheumatological laboratory (1996) (6)
A perspective on anti-cytokine and anti-T cell-directed therapies in rheumatoid arthritis. (1995) (6)
Cellular immunity in herpes simplex keratitis. (1973) (6)
Function and Regulation of the Murine Lymphocyte CD2 Receptor (1991) (6)
Circulating immune complexes (CIC) in connective tissue diseases (CTD). (1984) (6)
The 2005 International Symposium on Advances in Targeted Therapies: What have we learned in the 2000s and where are we going? (2005) (6)
Antibodies to the 65 kDa mycobacterial stress protein in west Africans with rheumatoid arthritis, tuberculosis and malaria. (1995) (5)
Anti-nRNP anti-nuclear antibody-secreting cells are represented in the B-lymphocyte repertoire of normal and MRL/MP-lpr/lpr lupus mice. (1988) (5)
Correction: Interleukin-6: a new therapeutic target (2006) (5)
Paediatric rheumatology Suppression of fever and the acute-phase response in a patient with juvenile chronic arthritis treated with monoclonal antibody to tumour necrosis factor-α (cA2) (1997) (5)
The clinical and pathogenetic significance of rheumatoid factors. (1978) (5)
Effect of histamine on the mitogenic response of human lymphocytes and its modification by cimetidine and levamisole (1981) (5)
CD5 (Ly-1)-negative, conventional splenic B cells make a substantial contribution to the bromelain plaque-forming cell response in CBA and BW mice. (1990) (5)
Characterisation of non-histone nuclear proteins cross reactive with purified rheumatoid factors. (1985) (5)
The significance of leucocyte migration inhibition by M. fermentans. (1975) (5)
Affinity Maturation and Isotype Switch in Clonally Related Anti‐Erythrocyte Autoantibodies (1994) (5)
A study of delayed hypersensitivity, lymphocyte transformation and leucocyte migration inhibition by M. xenopi and M. tuberculosis in patients harbouring these organisms. (1974) (4)
Sulphasalazine induced hepatitis in adult Still ' s disease (2004) (4)
TNF as a therapeutic target (2000) (4)
MRL-lpr/lpr mice show an impairment of IgG aggregate removal which relates to parameters of disease activity. (1987) (4)
The frequency of circulating immune complexes in rheumatoid arthritis and systemic lupus erythematosus (1982) (4)
Immunopathological mechanisms in rheumatoid arthritis at the dual interface of the synovial membrane: the joint cavity and the pannus. (1979) (4)
Clinical associations of IgG antibodies to the ribonucleoprotein p67 polypeptide in patients with systemic lupus erythematosus. (1992) (4)
Circulating immune complexes: current concepts of their pathogenetic role and methods of detection. (1978) (4)
Infliximab attenuates joint destruction in early RA patients with ultrasonographic markers of poor prognosis. (2002) (4)
Lymphocyte Mitogenic Factor in Cell-Mediated Immunity (1971) (4)
Autoimmunity to La (SS-B) in vitro is related to HLA-DR3 in healthy subjects. (1988) (4)
Insights into the pathogenesis of rheumatoid arthritis from application of anti-TNF therapy. (2000) (4)
IgG and IgM antibodies in systemic lupus erythematosus [proceedings]. (1976) (4)
Role of thymic and bursal lymphocyte subclasses in chronic allergic synovitis in the chicken. (1973) (3)
Introducing Arthritis Research & Therapy's 10th anniversary issue, 'The Scientific Basis of Rheumatology: A Decade of Progress' (2008) (3)
From the laboratory to the clinic: Evaluation of cytokines in rheumatoid arthritis highlights TNF-alpha as a new therapeutic target (1994) (3)
Separation oftwomolecular species oftheSmantigen byaffinity chromatography withmurine monoclonal and humananti-nuclear autoantibodies (1983) (3)
An investigation into the differential stability of Sm polypeptides using human and murine monoclonal antibodies. (1985) (3)
Partnership success. (1987) (3)
Prospects for cytokines in human immunotherapy (1994) (3)
In vivo fate of 125I SS-B (La) injected into mice. (1983) (3)
Arthritis Research: more than a journal (http://arthritis-research.com) (1999) (3)
The association between HLA-DR3 and antibodies to the nuclear ribonucleoprotein La: differences between patients from northern Europe and those from the Indian subcontinent. (1991) (3)
Immunoglobulin V genes expression and mRNA sequencing in rheumatoid arthritis. (1990) (3)
Increased representation of a subpopulation of early B cells in the peripheral blood of patients with rheumatoid arthritis. (1985) (3)
Identification and purification of a 55K polypeptide in Sjögren's syndrome A antigen (2004) (3)
The consequences of the Calman Report on academic rheumatology. (1996) (2)
OP0087 Infliximab plus methotrexate inhibits structural damage, reduces sign and symptoms and improves disability in patients with active early rheumatoid arthritis (2001) (2)
Relationship ofprecipitating antibodies tosoluble cellular antigens andhistologically defined renal lesions insystemic lupus erythematosus (1983) (2)
Effect of infliximab and methotrexate on radiographic progression in patients with early rheumatoid arthritis (2005) (2)
Possible role of lymphokines in the development of ectopic lymphoid foci in the chicken. (1973) (2)
Identification of hybridomas derived from mouse CD5+ B lymphocytes by fluorescent staining for cytoplasmic CD5 expression. (1994) (2)
Antibodies toextractable nuclear antigens inrheumatoid arthritis :relationship tovasculitis and circulating immunecomplexes (1980) (2)
Distribution of idiotypes in human autoimmune disease (1988) (2)
Workshop report (1983) (2)
Eular workshop on Rheumatology Research (1982) (2)
Proceedings: Heterogeneity of human synovial tissue cultures. (1974) (2)
Definition of TNFα as a therapeutic target for rheumatoid arthritis (2004) (2)
Lack of natural antibodies in rheumatic diseases (1988) (2)
Early RA patients on infiliximab therapy show significant changes in sonographic measures of joint vascularity and serum VEGF by 18 weeks. (2001) (2)
studyofcytomegalovirus andEpstein-Barr virus in rheumatoid arthritis andsicca syndrome (1985) (1)
Challenges and opportunities of publishing supplements at Arthritis Research & Therapy (2010) (1)
Demonstration ofanunidentified 48kDpolypeptide incirculating immunecomplexes inrheumatoid arthritis (1987) (1)
The debut of anti-TNF therapy of rheumatoid arthritis in the clinic (2000) (1)
Third Eular Workshop on Rheumatology Research (1983) (1)
Rapid clearance of the lupus antigen Sm is delayed by autoantibody: a possible mechanism of autoimmunity perpetuation. (1989) (1)
Long-term safety of infliximab and prevention of joint damage in patients with rheumatoid arthritis: Results of the attract trial (2000) (1)
Diagnostic role of antikeratin antibodies in RA. (1992) (1)
The Role of TNFα in the Pathogenesis of Rheumatoid Synovitis (1999) (1)
Nuclear and cytoplasmic antigens and antibodies—antibody profiles (1987) (1)
An overview of research into ankylosing spondylitis and rheumatoid arthritis. (1988) (1)
IgG antibodies to SS-B (La), RNP/Sm and DNA are produced by PWM-stimulated normal human lymphocytes in culture (2004) (1)
Professor Marc Feldmann and Sir Ravinder N. Maini Receive 2003 Albert Lasker Award for Clinical Medical Research (2004) (1)
Specific autoantibody slows the rapid plasma clearance of 125I-SS-B (La) in mice. (1984) (1)
Abstracts of the 23rd European Workshop for Rheumatology Research, Marseille, France, 27 February - 2 March 2003. (2003) (1)
Rheumatoid Arthritis (1992) (1)
Search for mycoplasma in synovial fluids from patients with rheumatoid arthritis. (1973) (1)
Ultrasonographic and radiographic evidence of attenuated joint destruction in early RA patients treated with infliximab (2003) (1)
Cell-mediated immunity to micro-organisms in rheumatoid arthritis. (1971) (1)
Characterization of the Sm antigen by using monoclonal antibodies (1985) (1)
Comment on the reply by Boers (2002) (1)
TREATMENT OF RHEUMATOID-ARTHRITIS WITH ANTIBODY TO TNF-ALPHA DECREASES EXPRESSION AND SHEDDING OF E-SELECTIN (1995) (1)
Targeting TNFα for the therapy of rheumatoid arthritis (1994) (1)
Quantitative aspects of serum anti-DNA measurements (1975) (1)
Immunology of rheumatic diseases: Gupta, S. and Talal, N., vii + 818 pp. Plenum Medical, New York, 1985. £69.50, ISBN 0-306-41987-4 (1987) (1)
Workshop summary: health outcomes and health economic issues surrounding the use of biological therapies in patients with rheumatoid arthritis. (1999) (1)
The immune response to autoantigens and viruses in rheumatic disease. (1991) (1)
Tissue uptake and catabolic studies of 125I SS-B (La) injected into mice. (1984) (1)
The detection by immunofluorescence of distinct cell populations producing interleukin-1 alpha and interleukin-1 beta in activated human peripheral blood. (1989) (1)
Immunoglobulin Variable Region (IgV) Gene Expression in Rheumatoid Factors from Monozygotic Twins with Rheumatoid Arthritis (1997) (1)
HLA andrheumatoid arthritis: a combined analysis of440British patients (1986) (1)
Antinuclear antibody determination methods (1990) (1)
CD5+B cells in rheumatoid arthritis and Sjögren's syndrome. (1990) (1)
Antineutrophil cytoplasmic antibody titres in patients with recent infection. (1993) (1)
Clinical andradiological features ofosteonecrosis in systemic lupus erythematosus (1979) (0)
Newer Biologics Hold Promise (2008) (0)
Clinical associations ofIgGantibodies tothe ribonucleoprotei n p67polypeptide inpatients with systemic lupuserythematosus (1992) (0)
Immunomodulation of Cytokines and T Cells by Biologicals in Rheumatoid Arthritis (2020) (0)
Arthritis Research: the move to publish research articles in full online only (2002) (0)
Immunological investigation of connective tissue diseases by L. E. Glynn and C. A. Reading, Churchill Livingstone, 1981. £15.00 (x + 98 pages) ISBN 0 443 01850 2. (1982) (0)
Book Review: Diagnostic Immunology (1983) (0)
Arthritis Therapy in Rheumatoid α Anti-TNF-and Acute-Phase Proteins Following Regulation of Cytokines , Cytokine Inhibitors , (1999) (0)
Production of monoclonal antibodies to the La antigen (1985) (0)
Deletion TNFalpha and IL-12 in therapy. (1997) (0)
Adverse reactions to Zn1-24 ACTH therapy associated with specific cellular immunity. (1975) (0)
Antibodies tonuclear antigens inpolymyositis: relationship toautoimmune 'overlap syndromes' andcarcinoma (1981) (0)
Synthesis ofsuiphated proteoglycans byrheumatoid andnormal synovial tissue inculture (1979) (0)
Sjogrens syndrome salivary gland epithelium expresses an antigen reactive with a monoclonal antibody to htlv 1 p19 gag protein (1990) (0)
[Study of the expression of the interleukin 2 receptor on the lymphocytes of patients with multiple sclerosis using anti-Tac monoclonal antibodies]. (1987) (0)
Scleroderma-associated antigens (1994) (0)
Reduction in radiographic progression in the hands and feet of patients with early rheumatoid arthritis after receiving infliximab in combination with methotrexate (2005) (0)
Hypotheses on basic mechanisms arising from recent research: antinuclear antibodies. (1987) (0)
Rheumatology. An Annual Review. Volume 5. Immunosuppression and Systemic Lupus Erythematosus (1975) (0)
Rheumatoid Arthritis: Recent Research Advances (2011) (0)
The Clinical Implications of Autoantibody Detection in Rheumatology (1993) (0)
Remicade^【○!R】 (infliximab) : Two Year Results from the ATTRACT Study Demonstrate Sustained Benefits in Signs and Symptoms, Structural Damage and Physical Function in Patients with Rheumatoid Arthritis (2001) (0)
Correction (1983) (0)
ARTHRTIS WITH AN ANT-TNF-ALPHA ANTIBODIES AND METHOTREXATE (2017) (0)
Manual of Biological Markers of Disease. Kluwer Academic Publishers, Chur/Victoria/Paris/Berlin/Tokyo/Amsterdam/Langhorne (1997) (1998) (0)
Both Ly-1 B cells and conventional B cells make autoantibodies to bromelain-treated autologous erythrocytes. (1988) (0)
Ultrasonographic evidence of attenuated joint destruction within 18 weeks in early RA patients treated with infliximab. (2003) (0)
Discordance between power Doppler and DAS28 assessment of remission induction in a randomised, placebo-controlled stud of infliximab therapy in early rheumatoid arthritis (2005) (0)
The co-localisation of tumour necrosis factor a (Tnf) and its receptor in rheumatoid arthritis (ra) synovial membrane. (1991) (0)
MULTIPLE ADMINISTRATIONS OF ANT-TNF ANTIBODY RELATED APPLICATIONS (2017) (0)
IX Eular Workshop for Rheumatology Research (1989) (0)
Anti-Sm and Anti-La Murine Monoclonal Antibodies: Characterisation of the Antigens (1985) (0)
Purification of antigens and monoclonal antibodies (1987) (0)
Long-term beneficial responses to therapy with a monoclonal antibody to TNF-alpha in patients with rheumatoid arthritis (1994) (0)
CYTOKINES IN RHEUMATOID ARTHRITIS : IS TNFα OF HAAJOR IMPORTANCE? (1993) (0)
Quantitative power Doppler and greyscale ultrasound demonstrate an association between vascularity and erosions in early rheumatoid arthritis (2001) (0)
Lymphokine Production in Autoimmunity: Usefulness of mRNA Assays (1987) (0)
Proceedings: Ocurrence of DNA-antibodies in antinuclear factor containing sera and a comparison with immunofluorescence. (1973) (0)
Correction Correction: Interleukin-6: a new therapeutic target (2006) (0)
Xth European Workshop for Rheumatology Research (2005) (0)
Antinuclear antibodies and complement in rheumatic diseases. (1977) (0)
XIth European Workshop for Rheumatology Research (2005) (0)
Mechanisms of Cytotoxicity and the Cells Involved (1981) (0)
From bench to bedside: evolution of anti-TNFalpha therapy in rheumatoid arthritis (2009) (0)
Rheumatology and Immunology (1981) (0)
Special Lectures on the Pathogenesis and the Pathogenesis-based Treatment of Rheumatoid Arthritis. Insights into the pathogenesis of rheumatoid arthritis from application of anti-TNF therapy. (2000) (0)
Anti-TNF / TNF receptor and methotrexate in the treatment of autoimmune diseases. (1997) (0)
Front & Back Matter (2012) (0)
MeasurementofDNA antibodies bydouble antibody precipitation (1973) (0)
Epstein-Barr virus DNA and early antigens in salivary gland biopsies from patients with Sjögren's syndrome and controls (1989) (0)
REDUCTION OF TNFalpha AND IL-12 IN THERAPY (1997) (0)
Comparison of remission induction in erosive early KA assessed by DAS28 calculated using either ESR or CRP in infliximab plus MTX combination therapy or MTX monotherapy (2005) (0)
SIGNIFICANT CHANGES IN SONOGRAPHIC MEASURES OF JOINT VASCULARITY AND SERUM VEGF IN EARLY RA PATIENTS ON INFLIXIMAB BY 18 WEEKS OF THERAPY (2002) (0)
What's Next for Biologics? (2008) (0)
Originals Interleukin-6 loealisation in the synovial membrane in rheumatoid arthritis (0)
Autoimmunity to La ( SSB ) in vitro is related to HLA-DR 3 in healthy subjects (2004) (0)
JOINT DESTRUCTION IS ATTENUATED BY INFLIXIMAB IN EARLY RA PATIENTS WITH ULTRASONOGRAPHIC MARKERS OF POOR PROGNOSIS (2003) (0)
The role of tumour necrosis factor in rheumatoid arthritis (2004) (0)
Use of monoclonal anti-La antibodies to study the concentration and distribution of La in normal and transformed cells (1985) (0)
CD5 + B Cells and Double-Negative T Cells in Rheumatoid Arthritis (1992) (0)
EXTRA‐ARTICULAR MANIFESTATIONS IN RHEUMATOID ARTHRITIS–CLINICAL and IMMUNOLOGICAL FEATURES (1978) (0)
Closing remarks (2004) (0)
Anti-TNF Antibodies and Methotrexate in the accompanying treatment of autoimmune diseases (1997) (0)
Immunotherapy of Autoimmune Diseases (1998) (0)
Individual variation ofanti-Sm autoantibodies inthe MRL/MP-lpr/lpr mouse: age-related increase indiversity (1986) (0)
Association between radiographic progression and persistent vascular signal on power doppler imaging in early rheumatoid arthritis (2006) (0)
Autoimmunity toLa(SS-B) invitroisrelated to HLA-DR3inhealthy subjects (1988) (0)
theB-lymphocyte repertoire ofnormalandMRL/MP-lpr/lpr Lupusmice (1988) (0)
Treatment of autoimmune and entzundungskrankheiten (1993) (0)
Hypotheses on basis mechanisms arising from recent research (1987) (0)
Comparison of ultrasonographic measures of synovitis and radiographic assessment of structural damage over two years in a randomised, controlled trial of infliximab therapy in erosive early rheumatoid arthritis. (2004) (0)
High levels of anti-type II collagen IgG in west African patients with rheumatoid arthritis. (1994) (0)
Antibody class differences are detected in anti-nRNP and anti-Sm antibodies directed against distinct antigen subunits (2004) (0)
High frequency power Doppler ultrasound reveals hypervascular erosions are common in early rheumatoid arthritis (2001) (0)
anti-TNF antibodies and methotrexate in the treatment of autoimmune diseases concomitant (1997) (0)
Administrations multiples d'anticorps diriges contre le facteur necrosant des tumeurs (anticorps anti-tnf) (1995) (0)

This paper list is powered by the following services:

Other Resources About Ravinder N. Maini

en.wikipedia.org

What Schools Are Affiliated With Ravinder N. Maini?

Ravinder N. Maini is affiliated with the following schools:

Imperial College London

Image Attributions

Image Source for Ravinder N. Maini